Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 17.39% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -26.03%. Over the past 30 days, the price of GANX has leaped by -6.36%. And in the last five days, it has fallen by -8.47%.
The stock of Gain Therapeutics Inc (GANX) is currently priced at $1.62. In the last session, the stock climbed significantly, topping out at $12.0 after opening at $1.62. The day’s lowest price was $5.0 before the stock closed at $1.7.
Gain Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $3.19 on 10/17/24 and the lowest value was $0.89 on 08/13/24.
52-week price history of GANX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Gain Therapeutics Inc’s current trading price is -49.22% away from its 52-week high, while its distance from the 52-week low is 82.02%. The stock’s price range during this period has varied between$0.89 and $3.19. The Gain Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.94 million for the day, a figure considerably higher than their average daily volume of 0.28 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Gain Therapeutics Inc (GANX) has experienced a quarterly decline of -13.37% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 48.51M and boasts a workforce of 25 employees.
Gain Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 4 analysts are rating Gain Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.8963, with a change in price of -0.7200. Similarly, Gain Therapeutics Inc recorded 287,510 in trading volume during the last 100 days, posting a change of -30.77%.
GANX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for GANX stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.06.
GANX Stock Stochastic Average
As of today, Gain Therapeutics Inc’s raw stochastic average for the last 50 days stands at 14.72%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 18.29%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 37.14% and 42.74%, respectively.
